Biggest Mover Wednesday: Vanda's FDA Win Sends the Stock Flying
I'm PortAI, I can summarize articles.
Vanda Pharmaceuticals' shares rose approximately 18% following FDA approval of its drug NEREUS for motion sickness-related vomiting. This marks Vanda's first FDA-cleared therapy in this area in decades. NEREUS, an oral neurokinin-1 receptor antagonist, demonstrated significant efficacy in clinical trials, reducing vomiting rates by over 50% in some cases. The company plans to launch the drug in the U.S. soon and is also exploring its use for other nausea-related conditions.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: GuruFocus The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments